Giving Harvoni to patients with the more aggressive genotype 3 strain of the disease who have cirrhosis and previous drug treatment would cost a much bigger £105,761, according to NICE.

In particular, treatments Harvoni and Viekira Pak both achieve higher QALYs with reduced costs, which makes the benchmark treatment no longer efficient, whereas treatments olysio + sovaldi and ...